Home » 2018 » December
InventisBio out-licenses lung cancer drug D-0316 to Betta Pharma

InventisBio out-licenses lung cancer drug D-0316 to Betta Pharma

InventisBio (Shanghai) has agreed to out-license the rights of its EGFR-T790M tyrosine kinase inhibitor D-0316 in China, Hong Kong and Taiwan to Betta Pharma, in a deal worth more than RMB230 million ($33.44 million). The two Chinese pharma companies have forged a partnership to co-develop the drug in China. D-0316, which was discovered by InventisBio, […]

Spectrum seeks ROLONTIS approval for chemotherapy-induced neutropenia

US biotech company Spectrum Pharmaceuticals said that it has submitted a Biologics License Application (BLA) for ROLONTIS (eflapegrastim) to the US Food and Drug Administration (FDA), seeking approval for the drug to be used as a treatment for chemotherapy-induced neutropenia. The BLA for ROLONTIS is backed by findings of two similarly designed phase 3 clinical […]

Continue reading …
Teva launches Elidel (Pimecrolimus) Cream, 1% generic version in US

Teva Pharmaceutical Industries has launched a generic version of Elidel (pimecrolimus) Cream, 1% in the US, a topical prescription medicine indicated for use as a second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis). Elidel (pimecrolimus) Cream, 1% has approval to be used for the treatment of non-immunocompromised […]

Continue reading …
FDA accepts to review NDA of Kala’s dry eye drug KPI-121 0.25%

The US Food and Drug Administration (FDA) has accepted to review the New Drug Application (NDA) for KPI-121 0.25%, an investigational dry eye drug, developed by Kala Pharmaceuticals. The US biopharma company is seeking the FDA approval for KPI-121 0.25% to be used for providing temporary relief of signs and symptoms of dry eye disease […]

Continue reading …
Vedanta Biosciences secures $27m to advance microbiome-derived drugs

US clinical stage company Vedanta Biosciences has raised $27 million in a Series C financing round to help it advance its pipeline of microbiome-derived product candidates. Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and the company’s founder PureTech Health took part in the new investment round. Vedanta […]

Continue reading …
Lupin out-licenses MALT1 inhibitor program to AbbVie in $977m deal

Indian pharma company Lupin has out-licensed its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program to US biopharma company AbbVie in a deal potentially worth around $977 million. Lupin and AbbVie have forged a partnership in this regard which gives the US biopharma company the exclusive global rights to develop and commercialize the […]

Continue reading …
Novartis proposes to acquire French CDMO CellforCure from LFB

Novartis has proposed to acquire French contract development and manufacturing organizations (French CDMO) CellforCure from LFB for an undisclosed price. CellforCure is engaged in producing cell and gene therapies across Europe. The deal proposed by Novartis includes the cell and gene manufacturing facility in Les Ulis near Paris and the related adjacent land. If the […]

Continue reading …
Amgen seeks FDA approval for infliximab biosimilar ABP 710

Amgen has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to Johnson & Johnson’s REMICADE (infliximab). ABP 710 is being studied as a biosimilar candidate to infliximab, which is an anti-tumor necrosis factor alpha (anti-TNF) monoclonal antibody. Infliximab has approval in several regions […]

Continue reading …
Incyte, Innovent announce collaboration for three cancer drugs in China

US pharma company Incyte and Chinese biopharma company Innovent Biologics through their respective subsidiaries have entered into a deal worth up to $391.5 million for three investigational cancer drugs discovered and developed by the former. The three investigational cancer drugs – pemigatinib, a FGFR1/2/3 inhibitor, itacitinib, a JAK1 inhibitor and parsaclisib, a PI3Kδ inhibitor, are […]

Continue reading …
Japanese pharma company Astellas acquires Potenza Therapeutics

Astellas acquisition of Potenza : Japanese pharma company Astellas Pharma has exercised an option to acquire US-based Potenza Therapeutics in a deal worth up to $404.7 million. The acquisition is a result of a collaboration agreement signed by the two pharma companies in 2015 to develop a portfolio of novel immuno-oncology (IO) therapies. In the […]

Continue reading …
Page 1 of 3123